<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888186</url>
  </required_header>
  <id_info>
    <org_study_id>DYSK-PD-2007</org_study_id>
    <nct_id>NCT00888186</nct_id>
  </id_info>
  <brief_title>Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics</brief_title>
  <acronym>DYSK-PD-2007</acronym>
  <official_title>Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Parkinson's Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Society for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study different kinds of dyskinesias in advanced Parkinson's
      disease appearing at different levels of levodopa infusion dose. The hypothesis is that
      different dyskinesias (dystonia, chorea) correlate to different levels of levodopa
      concentrations, as detected in plasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By using duodenal infusion of levodopa/carbidopa, the plasma concentration of levodopa can be
      kept fairly constant. Different doses, 10-20% higher or lower than the individually optimized
      dose will be used. Motor performance is captured by video recordings to be compared
      to/correlated with plasma levodopa concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between plasma levodopa concentration and choreatic dyskinesia, dystonia, and parkinsonism</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between choreatic dyskinesia, dystonia, and parkinsonism.</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Dyskinesias</condition>
  <arm_group>
    <arm_group_label>1. Duodopa optimal dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Duodopa 20% too high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Duodopa 10% too low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Duodopa 20% too low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5. Duodopa 10% too high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levodopa/carbidopa</intervention_name>
    <description>intestinal gel, for continuous daytime infusion</description>
    <arm_group_label>1. Duodopa optimal dose</arm_group_label>
    <arm_group_label>2. Duodopa 20% too high dose</arm_group_label>
    <arm_group_label>3. Duodopa 10% too low dose</arm_group_label>
    <arm_group_label>4. Duodopa 20% too low dose</arm_group_label>
    <arm_group_label>5. Duodopa 10% too high dose</arm_group_label>
    <other_name>Duodopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of idiopathic Parkinson's disease

          -  Ongoing treatment with Duodopa

          -  Occurrence of dyskinesias, difficult to manage

          -  Age 30-90 years

          -  Hoehn &amp; Yahr stage 3-5 at worst

        Exclusion Criteria:

          -  Treatment with dopamine agonist or glutamate antagonist

          -  Dementia

          -  Psychosis

          -  Treatment with typical neuroleptics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005 Jan 25;64(2):216-23.</citation>
    <PMID>15668416</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <last_update_submitted>April 24, 2009</last_update_submitted>
  <last_update_submitted_qc>April 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dag Nyholm, MD, PhD</name_title>
    <organization>Uppsala University</organization>
  </responsible_party>
  <keyword>Dyskinesias</keyword>
  <keyword>Duodenal levodopa infusion</keyword>
  <keyword>Dose optimization</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

